Targeting the Gut-Heart Axis Improves Cardiac Remodeling in a Clinical Scale Model of Cardiometabolic Syndrome
- PMID: 39906593
- PMCID: PMC11788474
- DOI: 10.1016/j.jacbts.2024.09.004
Targeting the Gut-Heart Axis Improves Cardiac Remodeling in a Clinical Scale Model of Cardiometabolic Syndrome
Abstract
Poor diet, gut dysbiosis, and systemic inflammation constitute a gut-heart axis (GHA) that may affect heart failure with preserved ejection fraction. Clinical scale models to interrogate this axis are limited. Here, we show the full extent of the GHA-gut barrier function loss, systemic and microvascular inflammation, and its colocalization with apoptosis (left atrium) and hypertrophy (left ventricle). Gut barrier function primacy in regulating the GHA is supported by a synbiotic intervention that shuts down gut epithelial permeability, markedly decreasing systemic inflammation and, remarkably, cardiac structural changes in left heart chambers. These data support a new paradigm for targeting heart failure with preserved ejection fraction via the GHA.
Keywords: heart failure; metabolic syndrome; microbiome; synbiotic.
© 2025 The Authors.
Conflict of interest statement
This study was funded by a grant from Tate and Lyle Solutions USA LLC and by a grant from Science Foundation Ireland to the Alimentary Pharmabiotic Centre at University College Cork, grant number 12/RC/2273-P2. Drs Herisson, Karnik, Laurie, Canene-Adams, Ross, Stanton, Caplice are named inventors on intellectual property co-owned by University College Cork and Tate and Lyle Solutions, LLC relating to synbiotic treatment of metabolic syndrome. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures






Comment in
-
Synbiotics and Gut-Heart Axis in Cardiometabolic Disease.JACC Basic Transl Sci. 2025 Jan 27;10(1):16-19. doi: 10.1016/j.jacbts.2024.11.008. eCollection 2025 Jan. JACC Basic Transl Sci. 2025. PMID: 39958467 Free PMC article.
References
-
- Borlaug B.A., Sharma K., Shah S.J., Ho J.E. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810–1834. - PubMed
-
- Usman M.S., Siddiqi T.J., Anker S.D., et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377–2387. - PubMed
-
- Murphy S.P., Kakkar R., McCarthy C.P., Januzzi J.L. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(11):1324–1340. - PubMed
LinkOut - more resources
Full Text Sources